Key result
Apixaban fails to prevent acute lower-extremity DVT in a patient with nonvalvular AF.
Why the study?
Cases of treatment failure with novel oral anticoagulants due to interindividual variation in plasma drug levels are rarely seen but clinically important.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
This case highlights the rare possibility of treatment failure and acute DVT development in patients taking apixaban for VTE prevention.
The efficacy of novel oral anticoagulants (NOACs) in preventing deep venous thrombosis (DVT) has been established in large multicenter trials. Predictable pharmacokinetics, avoidance of routine laboratory monitoring, and lesser drug interactions have made NOACs safer and more tolerable treatment option in comparison to warfarin. However, cases of treatment failure mainly due to interindividual variation in plasma drug levels can be seen rarely. In this report we describe a case of acute DVT of right lower extremity in a patient who was on apixaban for prevention of venous thromboembolism (VTE) due to underlying nonvalvular atrial fibrillation (NVAF).
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2017) conducted a case report in Nonvalvular atrial fibrillation (NVAF) (n=1). Apixaban was evaluated on Acute deep venous thrombosis (DVT). A patient with nonvalvular atrial fibrillation developed acute deep venous thrombosis of the right lower extremity despite being on apixaban for venous thromboembolism prevention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: